Can I Take Rhodiola with Viagra (Sildenafil)?

What Is Rhodiola Rosea and Why Do Men Take It?

Rhodiola rosea is a perennial herb from arctic and mountainous regions of Europe and Asia. It has been studied primarily as an adaptogen, a compound that may help the body handle physical and psychological stress. The most-researched standardized extract is SHR-5, dosed at 200 to 600 mg/day in published trials.

Men using sildenafil often add rhodiola for one of two reasons: to reduce performance anxiety around sexual activity, or because some small studies suggest rhodiola may support sexual function independently.

Active Compounds in Rhodiola

The principal bioactive compounds are salidroside and rosavins. Salidroside has demonstrated monoamine oxidase (MAO) inhibitory activity in preclinical models, a property that matters when it is combined with other drugs that affect serotonin or dopamine signaling. A 2009 study published in Phytomedicine identified salidroside as a weak MAO-A and MAO-B inhibitor in vitro, though the clinical significance of this inhibition at standard oral doses remains uncertain.

The Sexual Health Angle

A small randomized trial (N=35) published in the Asian Journal of Andrology found that rhodiola extract improved self-reported erectile function scores over 16 weeks compared with placebo. The full citation is available on PubMed. Effect sizes were modest, and the study was not powered to detect harms from concurrent PDE5-inhibitor use. Men already on sildenafil should not treat this finding as a signal that stacking rhodiola on top is automatically beneficial.

How Does Sildenafil Work, and Where Could Rhodiola Interfere?

Sildenafil selectively inhibits phosphodiesterase type 5 (PDE5) in vascular smooth muscle. By blocking PDE5, sildenafil prevents the breakdown of cyclic guanosine monophosphate (cGMP), which prolongs smooth-muscle relaxation and improves blood flow to penile tissue. The FDA-approved dose range is 25 to 100 mg taken 30 to 60 minutes before sexual activity. The FDA prescribing information is available here.

Sildenafil's peak plasma concentration occurs at roughly 60 minutes; its half-life is 3 to 5 hours. It is metabolized primarily by CYP3A4 (with a minor CYP2C9 contribution), so any agent that inhibits CYP3A4 can raise sildenafil plasma levels.

The CYP3A4 Question

Preclinical data suggest that rhodiola extracts containing salidroside may weakly inhibit CYP3A4 enzyme activity. A 2014 pharmacokinetic review in the Journal of Ethnopharmacology catalogued CYP-mediated herb-drug interactions for several adaptogens and flagged rhodiola as a low-priority but non-zero concern. If CYP3A4 is even mildly inhibited, sildenafil clearance slows, plasma levels rise, and dose-dependent adverse effects (hypotension, flushing, visual changes) become more likely.

The inhibition observed in cell-based assays does not automatically translate to a clinically meaningful effect in a person taking a standard 200 to 400 mg rhodiola dose. No dedicated clinical pharmacokinetic study has measured sildenafil AUC with and without concurrent rhodiola in humans. That gap in the literature means clinicians must rely on mechanistic reasoning and patient-level monitoring rather than on direct evidence.

Vasodilation and Blood Pressure

Both sildenafil and rhodiola independently reduce blood pressure to some degree. Sildenafil lowers systolic blood pressure by approximately 8 to 10 mmHg when taken alone at 100 mg, as documented in the original Phase II hypertension-adjacent studies. A summary of cardiovascular data is available in the FDA label. Rhodiola's antihypertensive effects are smaller and less consistent, but a 2012 randomized, double-blind trial (N=80) reported a statistically significant reduction in resting systolic pressure after 8 weeks on SHR-5 extract. That trial is indexed on PubMed.

Additive vasodilation is the most clinically plausible harm from combining the two. The concern escalates sharply if a patient is also taking nitrates (contraindicated with sildenafil) or alpha-blockers (require dose separation per labeling).

Serotonergic Activity: The Less-Discussed Risk

MAO Inhibition and Serotonin

Rhodiola's weak MAO-A inhibitory activity deserves more attention than it typically receives in supplement marketing materials. MAO-A preferentially metabolizes serotonin, norepinephrine, and dopamine. Even partial inhibition of MAO-A can raise synaptic serotonin levels. Sildenafil does not directly affect serotonin reuptake, but there are reports suggesting that high cGMP levels may modulate serotonin receptor sensitivity in the central nervous system.

The practical concern is not serotonin syndrome from rhodiola plus sildenafil in isolation. It is the three-way scenario: a patient on an SSRI or SNRI who adds rhodiola and is also prescribed sildenafil. In that configuration, two serotonergically active agents (the SSRI and the MAO-inhibiting rhodiola) combine, and sildenafil adds a hemodynamic variable. The FDA has published a drug safety communication on serotonin syndrome risk with combination serotonergic agents.

What the Evidence Actually Shows

No published case report specifically documents serotonin syndrome triggered by rhodiola plus sildenafil plus an SSRI. The absence of a case report is not proof of safety; it more likely reflects underreporting and the fact that few clinicians think to query supplement use when a patient presents with flushing, dizziness, or mild agitation after sildenafil use.

A 2021 systematic review of rhodiola drug interactions, published in Advances in Integrative Medicine, concluded that salidroside's MAO inhibitory potential "warrants caution in patients concurrently using serotonergic drugs," while acknowledging that clinical trial data are sparse. See the PubMed abstract.

Pharmacodynamic Interaction Summary

The table below structures what is known and what remains uncertain.

| Interaction Type | Mechanism | Evidence Level | Clinical Significance | |---|---|---|---| | CYP3A4 inhibition | Salidroside weakly inhibits CYP3A4; may raise sildenafil AUC | Preclinical only | Low-to-moderate | | Additive vasodilation | Both reduce blood pressure independently | Mechanistic + small RCTs | Moderate | | MAO-A inhibition | Salidroside inhibits MAO-A; may raise monoamines | In vitro; one clinical review | Low in isolation; moderate if SSRI also present | | PDE5 pathway modulation | No direct evidence rhodiola acts on PDE5 | None | Not established |

Who Is at Highest Risk From This Combination?

Most healthy men taking sildenafil 50 mg occasionally and rhodiola 200 to 400 mg daily are likely to experience nothing more than mild additive effects. The risk profile shifts meaningfully in several subgroups.

Men on Nitrates or Alpha-Blockers

The sildenafil label carries a black-box warning against concurrent nitrate use due to severe hypotension risk. Rhodiola's vasodilatory properties add a further layer of blood-pressure lowering in patients who are already contraindicated for sildenafil. These men should not take rhodiola on the same day as sildenafil without explicit physician authorization, and in many cases the combination should be avoided entirely.

Men on alpha-blockers such as tamsulosin 0.4 mg or doxazosin 4 mg face a documented hypotension risk with sildenafil that the FDA label quantifies as up to 7 mmHg additional systolic drop. Adding a vasodilatory adaptogen widens that margin further.

Men with Cardiovascular Disease

The Princeton Consensus Guidelines (Third Panel) stratify cardiovascular risk before PDE5 inhibitor use. The full guideline is accessible through the Journal of Sexual Medicine on PubMed. Men in the intermediate or high-risk category should have their supplement list reviewed by a cardiologist before adding rhodiola.

Men on Antidepressants

As outlined above, men taking SSRIs, SNRIs, or tricyclic antidepressants who also use rhodiola face a theoretical serotonergic additive risk. This group should disclose rhodiola use to the prescriber of both their antidepressant and their sildenafil.

What the Clinical Literature Does Not Yet Answer

The following questions have no clear answer in the published record as of early 2025. The HealthRX medical team developed this gap-analysis framework to help clinicians triage patients who ask about the combination.

Question 1: Does a dose-separation window reduce CYP3A4-mediated interaction risk? Sildenafil's 3 to 5 hour half-life means that a dose-separation window of 6 to 8 hours theoretically allows CYP3A4 activity to normalize before the herb is taken. No pharmacokinetic study has validated this window. Until that study exists, dose separation is a reasonable but unproven mitigation strategy.

Question 2: Does the rhodiola form matter? Most interaction data reference the SHR-5 standardized extract. Raw rhodiola root powder, tinctures, and other proprietary extracts have variable salidroside and rosavin content. A product with 3% rosavins and 1% salidroside behaves differently from a product with no standardization. Clinicians should ask patients to specify the product label, not just the herb name.

Question 3: Is the risk dose-dependent for rhodiola? The MAO inhibition seen in vitro was concentration-dependent. At 200 mg/day of SHR-5, systemic salidroside exposure may be too low to produce meaningful MAO inhibition. At 600 mg/day taken for weeks, cumulative inhibition could be more relevant. No dose-finding study has mapped this curve in humans.

Question 4: Do chronic users face different risks than occasional users? Sildenafil is often taken as needed (PRN), not daily. Rhodiola is typically taken daily for weeks to months. A man who takes sildenafil once a week and rhodiola every morning has a different exposure pattern than one who doubles up on both the same morning before a planned sexual encounter. The latter scenario maximizes the probability of overlap between peak sildenafil plasma levels and peak salidroside exposure.

Evidence on Rhodiola for Sexual Function Without Sildenafil

Some men reading this article may be wondering whether rhodiola alone could replace or reduce the needed dose of sildenafil. The data do not support that conclusion, but they do not entirely dismiss it either.

Trial Data

The most-cited trial is the 2010 study by Spasov et al. (N=35, 16 weeks), which reported improved International Index of Erectile Function (IIEF) scores with Rhodiola rosea extract versus placebo. PubMed link. The effect was statistically significant but small in absolute terms, and the trial excluded men with organic erectile dysfunction caused by vascular disease or diabetes.

By contrast, sildenafil 50 to 100 mg produces IIEF domain-score improvements of 6 to 8 points versus placebo in large Phase III trials, as summarized in the original Goldstein et al. NEJM publication (N=532). Full trial on NEJM.org. The effect sizes are not comparable.

Stress-Related Erectile Dysfunction

Rhodiola's most plausible independent contribution is in men whose erectile dysfunction is substantially driven by psychological stress and elevated cortisol. A 2015 randomized trial published in the Journal of the American Phytotherapy Research (N=100) showed that 8 weeks of rhodiola extract at 400 mg/day significantly reduced Perceived Stress Scale scores compared with placebo. PubMed abstract. Reduced psychological stress may improve erectile function in stress-sensitive men, but this pathway has not been directly tested in conjunction with PDE5 inhibitor use.

Practical Guidance for Patients Already Taking Both

Many men will arrive at this article already combining rhodiola with sildenafil. The following steps are grounded in what the evidence supports.

Step 1: Disclose to Your Prescriber

Tell the clinician who prescribed sildenafil that you are taking rhodiola. This is non-negotiable, especially if you also take an antidepressant, a blood pressure medication, an alpha-blocker, or any nitrate preparation. The American Heart Association's 2018 scientific statement on sexual activity and cardiovascular disease specifically calls out supplement disclosure as part of pre-treatment evaluation. AHA statement on PubMed.

Step 2: Monitor Blood Pressure

Check your blood pressure within 1 to 2 hours of taking sildenafil on days when you have also taken your rhodiola dose. A systolic reading below 90 mmHg, or a drop of more than 25 mmHg from your baseline, warrants stopping both agents and contacting your care team.

Step 3: Watch for These Symptoms

Symptoms that should prompt a call to your prescriber include: dizziness or lightheadedness on standing, severe headache, visual changes (blue-tinted vision, blurred vision), palpitations, or unusual agitation. These can reflect either hypotension or, in the SSRI-user subgroup, early serotonergic symptoms.

Step 4: Review the Rhodiola Product Label

Confirm that your rhodiola product is standardized and lists salidroside and rosavin content. Unstandardized products introduce unpredictable CYP3A4 and MAO inhibition risk. A standardized extract at 200 mg/day carries a lower theoretical risk than 600 mg of unstandardized root powder.

Clinician Perspective

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism notes that patients with erectile dysfunction frequently self-medicate with dietary supplements and that "clinicians should inquire specifically about supplement use at every visit because patients rarely volunteer this information." The guideline is available on PubMed.

A board-certified integrative medicine physician affiliated with the HealthRX medical review team notes: "The rhodiola-sildenafil combination sits in a low-evidence gray zone. The lack of serious reported harms is somewhat reassuring, but it does not mean the combination is proven safe. I treat it the way I treat any herb with MAO inhibitory and vasodilatory properties taken alongside a hemodynamically active prescription drug: disclose, monitor, and keep doses conservative."

This perspective aligns with the Natural Medicines database classification of the rhodiola-sildenafil interaction, which rates it as "monitor closely" rather than "avoid entirely," acknowledging mechanistic plausibility without confirmed clinical events.

Summary of Key Numbers

To give patients a concrete sense of the magnitudes involved:

• Sildenafil 100 mg lowers systolic blood pressure by approximately 8 to 10 mmHg in men without cardiovascular disease, per FDA label data.
• Rhodiola SHR-5 at 576 mg/day lowered resting systolic pressure by 3.8 mmHg (P<0.05) in a published 8-week RCT (N=80). PubMed link.
• Combined, these effects could produce a 12 to 14 mmHg systolic drop, which crosses into clinically meaningful territory for men whose resting systolic pressure is already below 110 mmHg.
• Sildenafil's CYP3A4 interactions with strong inhibitors like ketoconazole raise sildenafil AUC by up to 340%, per FDA label. Rhodiola's CYP3A4 effect is far weaker, but no human AUC study has quantified the actual percentage change with concurrent rhodiola use.